GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celcuity Inc (NAS:CELC) » Definitions » Net Income (Continuing Operations)

Celcuity (Celcuity) Net Income (Continuing Operations) : $-73.45 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Celcuity Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Celcuity's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was $-21.61 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was $-73.45 Mil.


Celcuity Net Income (Continuing Operations) Historical Data

The historical data trend for Celcuity's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celcuity Net Income (Continuing Operations) Chart

Celcuity Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only -7.36 -9.47 -29.61 -40.37 -63.78

Celcuity Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.94 -14.59 -18.41 -18.85 -21.61

Celcuity Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-73.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celcuity  (NAS:CELC) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Celcuity Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Celcuity's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Celcuity (Celcuity) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celcuity Inc (NAS:CELC) » Definitions » Net Income (Continuing Operations)
Traded in Other Exchanges
N/A
Address
16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446
Celcuity Inc is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. The company's therapeutic candidate is gedatolisib, a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all Class I isoforms of PI3K and the mammalian target of rapamycin (mTOR).
Executives
Richard E Buller director C/O CELCUITY INC., 16305 36TH AVE. N., #100, MINNEAPOLIS MN 55446
David Dalvey director C/O BLUE ROCK ADVISORS, INC., 80 SOUTH EIGHTH STREET SUITE 3915, MINNEAPOLIS MN 55402
Leo Furcht director C/O CELCUITY, 16305 36TH AVENUE N., #100, MINNEAPOLIS MN 55445
Brian F Sullivan director, 10 percent owner, officer: Chief Executive Officer 16305 36TH AVENUE N, MINNEAPOLIS MN 55446
Polly A. Murphy director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Richard Nigon director CEDAR POINT CAPITAL, 150 SOUTH 5TH STREET, MINNEAPOLIS MN 55402
Lance G. Laing director, 10 percent owner, officer: Chief Science Officer, VP C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Vicky Hahne officer: Chief Financial Officer C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Maureen Therese Cronin director C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446